Company / Interest Expense
Phathom Pharmaceuticals, Inc. Interest Expense History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$42.0M
FY2023
5-year range
$6.8M / $42.0M
FY2019-FY2023
Trend
+53.7%
vs FY2022
Sector context
#15 of 44
Health Care
What the data says
At $42M, Phathom Pharmaceuticals, Inc.'s interest expense ranks #30 of 44 in the Health Care sector. Interest Expense has increased for 5 consecutive years, from $13,000 in FY2018 to $42M in FY2023.
Based on SEC 10-K filings.
$42M in FY2023 with a 5-year CAGR of +403.3%.
Increased from $7M to $42M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +109.2%
- 5-Year CAGR
- +403.3%
- 10-Year CAGR
- -
Sector benchmark
#30 of 44 in Health CareTop 66% of 44This company $42.0M Sector average $291.0M
▼
-85.6% below sector average
Key checks
Key Insights
- Phathom Pharmaceuticals, Inc.'s interest expense has grown for 5 consecutive years.
- 5-year CAGR of +403.3%, indicating consistent growth.
- In FY2023, interest expense increased 53.7% year-over-year.
- Ranks #15 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $42.0M | +53.7% |
| FY2022 | $27.3M | +302.3% |
| FY2021 | $6.8M | +48.2% |
| FY2020 | $4.6M | +9.7% |
| FY2019 | $4.2M | +32030.8% |
| FY2018 | $13.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026